<DOC>
	<DOCNO>NCT01850446</DOCNO>
	<brief_summary>The purpose study : - ass efficiency Ergoferon treatment influenza ; - ass safety Ergoferon treatment influenza ; - compare efficiency Ergoferon Oseltamivir treatment influenza .</brief_summary>
	<brief_title>Comparative Clinical Trial Efficiency Safety Ergoferon Versus Oseltamivir Treatment Influenza</brief_title>
	<detailed_description>The overall duration patient participation trial 6 day ( screening/randomization/therapy onset - day 1 ; study therapy period - day 1-5 ; follow-up period - day 6 ) .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>1 . Patients age 18 70 year inclusively . 2 . Patients , admit hospital within 48 hour onset influenza sign . 3 . Patients body temperature ≥37,8°C visit doctor + intensity influenza symptom ≥4 score ( presence least 1 general symptom ≥2 score 1 nasal/ throat/ chest symptom ≥ 2 score great number symptom intensity ≥1 score ) . 4 . Diagnosed influenza confirm express diagnostics ( OSOM Influenza A &amp; B Test ) . 5 . The possibility start therapy within 48 hour onset first symptoms influenza . 6 . Usage contraceptive method gender patient reproductive age trial within 30 day end participation trial . 7 . Availability sign patient information sheet ( Informed Consent form ) participation clinical trial . 1 . Suspected pneumonia . 2 . Suspected initial manifestation diseases symptom similar influenza symptom ( acute respiratory infectious disease , influenzalike syndrome onset systemic connective tissue disorder , oncohematology pathology ) . 3 . Patients require competitive antiviral drug , prohibit trial . 4 . Medical history primary secondary immune deficiency : ) lymphoid system immunodeficiency ( Tcell and/or Bcell immunity chain , immunodeficiency predominant antibody deficiency ) ; b ) phagocyte deficiency ; c ) complement factor deficiency ; ) combine immunodeficiency include AIDS induce HIV infection ; toxic , autoimmune , infectious , radial panleukopenia syndrome ; general lymphocytopenia syndrome ; syndrome lymphocyte polyclonal activation ; postsplenectomia syndrome ; congenital asplenia ; syndrome immune complex pathology associate infectious , allergic autoimmune disease . 5 . Medical history sarcoidosis . 6 . Oncological disease/suspected oncological disease . 7 . Exacerbation decompensation chronic disease affect patient 's ability participate clinical trial . 8 . Medical history polyvalent allergy . 9 . Allergy/ intolerance component medication use influenza treatment . 10 . Impaired glucose tolerance , type 1 2 diabetes mellitus . 11 . Malabsorption syndrome , include congenital acquire lactose deficiency disaccharide deficiency . 12 . Exacerbation decompensation chronic disease affect patient 's ability participate trial . 13 . Pregnancy breast feed . 14 . Drug addiction , alcohol usage amount exceed 2 unit alcohol per day , mental disorder . 15 . Intake medicine list section `` Prohibited concomitant treatment '' 1 month prior inclusion trial . 16 . Patients , investigator 's point view , fail comply observation requirement trial intake regimen investigate medicine . 17 . Participation clinical trial course 1 month prior inclusion trial . 18 . Patient relate research personnel investigative site , directly involve trial immediate family member researcher . The immediate family member include husband/wife , parent , child brother ( sister ) , regardless whether natural adopt . 19 . Patient work OOO `` NPF `` Materia Medica Holding '' ( i.e . company 's employee , temporary contract worker appoint official responsible carry research ) immediate relative .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>